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Introduction
Tumor necrosis factor-a ( m a ) , originally named for its anti-tumor activity, is now recognized as a multifunctional mediator with effects on metabolism, inflammation, and cellular immune responses (1, 2) . Some of the cellular sources of TNF-a include macrophages (3), neutrophils (4), T-lymphocytes ( 5 ) , fibroblasts (6) , and mast cells (7, 8) . We recently used light microscopic methods for in situ hybridization and immunohistochemistry, as well as Northem blots, to idenufy M a mRNA and protein product in blood eosinophils isolated from patients with the idiopathic hypereosinophilic syndrome (HES) (9) . We also showed that highly purified blood eosinophils from atopic donors released TNF-a protein spontaneously in vitro (9) .
In this study we used a post-embedding ultrastructural immunogold approach to investigate the substructural location(s) of "F-a in human eosinophils. We detected TNF-a exclusively in the major eosinophil granule population of peripheral blood eosinophils from patients with the HES. Specifically ent in the matrix compartment of the crystalline core-containing, bicompartmental secondary granules (lo), but not in the lipid bodies (11) or in the primary (12) or small (13) granule populations, of eosinophils from patients with HES. However, TNF-a was not detected in the eosinophils of normal donors.
Materials and Methods
Blood Samples. Peripheral blood samples were obtained from two normal donors (2% and 4% eosinophils) and from two patients with HES (80% and 64% eosinophils).
Fixation. Leukocytes were carefully removed from the buffy coat layer with a Pasteur pipette and then were fixed in suspension for 30 min at room temperature (RT) in a mixture containing 4% paraformaldehyde, 0.5% glutaraldehyde, 0.025% calcium chloride in 0.1 M sodium cacodylate buffer, pH 7.4. After fixation the samples were washed three times in 0.1 M sodium cacodylate buffer (pH 7.4) at 2O' C for 3-5 min each.
Processing for Electron Microscopy. The cell samples were dehydrated and embedded in LR White resin (Polysciences; Warrington, PA), according to the protocol of Milici and Porter (14) . Briefly, two changes of 70% ethanol, 10 min each at 4°C. were followed by 70% ethanol (-20°C. 10 min), 80% ethanol (-2O'C, 10 min), and 95% ethanol (-20'C. 10 min). The cell suspensions were infiltrated in a 70:30 mixture of LR White resin in 95% ethanol for 1 hr, -20%. Between each change the cells were centrifuged at 1000 rpm at -4°C. The specimens were then infiltrated in 100% LR White (without accelerator) for 14 hr at -2O' C and were transferred BEE, WELLER, TZIZM, GALLI, DVORAK Gold particles are present in the matrix but not in the electronlucent central core areas of the specific granules in A$; the granules are not labeled in E. Specific eosinophil granules in cells from the same specimens were not labeled when normal rabbit serum was substituted for the primary antibody to TNF-a (C) or when the TNF-a antibody was absorbed with recombinant human TNF before use in immunogold staining (D). Bars: A-D = 0.15 pm; E = 0.6 pm.
to BEEM capsules (Ted Pella; Redding, CA). LR White resin (100%) with accelerator was added to the capsules and the blocks were allowed to polymerize for 24 hr at -20°C. The blocks were allowed to cure further at RT for at least 24 hr before sectioning. Thin sections were cut with a diamond knife on an LKB-V Ultratome (LKB Bromma, Sweden), placed on uncoated nickel grids (Pelco; Tustin, CA), and floated on drops of PBS (0.12 M. pH 7.4) before immunogold labeling.
Post-embedding Immunogold Labeling to Demonstrate TNF-a. The following sequence of steps was used to stain grids. which held 50-70-nm Figure 2 . Specific granules in the peripheral blood eosinophils of a patient with HES. (A) Preparation stained with primary TNF-a antibody exhibits extensive gold labeling of the specific granule matrix compartments. One of the specific granules has retained an electron-dense central core (arrowhead) and the core is not labeled. The focal lucencies exhibited by the core compartments of other granules are characteristic of HES eosinophils in these preparations. Note also the low labeling of the extracellular background. (B) A preparation incubated with normal rabbit serum instead of the primary antibody to TNF-a is negative. Percent of granules labeled in the sham-absorbed control for the absorption control (28%) is less than the percent of granules labeled when the standard procedure for labeling was used (64%). Approximately SO% reduction of label in the TNF-a-absorbed control occurred compared with the sham-absorbed control (49% reduction in the total number of gold panicles/total number of granules; 43% reduction in % of labeled granules). The sham-absorbed control is necessary to control for nonspecific losses of labeling during the method of preparation of the rhTNF-a-absorbed primary antibody.
Positive granules are defined as those associated with 25 gold particles. See Materials and Methods.
antibody (Genzyme) and incubated for 24 hr, 4'C. Seventy-five pI of PBSINSS (to dilute the primary antibody appropriately) were added to the microfuge tube caps, which were then placed on a shaker for 1 hr. The absorbed primary antibody and the sham-absorbed primary antibody were removed from the microfuge tube caps and substituted for the primary antibody in the immunogold staining protocol described above. After drying, all grids were stained for 4 min in 0.18% uranyl acetate and 0.02% methyl cellulose (25 centipoises; Sigma) in distilled water (15) and were examined in a Phillips 300 electron microscope (North American Philips; Mahwah, NJ).
Peripheral Blood Eosinophils of HES Patients
Immunogold labeling of TNFa was detected within the matrix compartment of 64% of the eosinophil-specific (secondary) bicompartmental granules (n = 1700) visualized in thin sections of 60 cells studied from two patients (30 cells from each patient) ( Figures  1A, 1B, and 2A) . The crystalloid core compartment of these granules often was focally electron lucent in HES peripheral blood eosinophils. When core material was visible, it was not detectably labeled for TNF-a Other eosinophil granule populations (i.e., primary and small granules), as well as lipid bodies and tubulovesicular structures, were not labeled for TNF-a, nor was nuclear or cytoplasmic staining detected. Golgi structures and rough endoplasmic reticulum are not major subcellular structures in mature eosinophils (10); those that were visible did not label for TNF-a in this study.
The plasma membrane of the eosinophils was not labeled, either with our standard post-embedding immunogold method or when we employed a pre-embedding immunogold method (Bed et al., unpublished data).
Normal Peripheral Blood Eosinophils
We examined thin sections of 30 peripheral blood eosinophils, containing 630 specific granules, obtained from two different normal donors (20 cells were from one donor; 10 cells were from the second donor). None of these cells exhibited detectable labeling for TNF-a ( Figure 1E ).
Specificity Controls
Omission of the primary antibody or substitution of normal rabbit serum ( Figures 1C and 2B) for the primary antibody resulted in absence of gold labeling of the specific granule matrix compart-ment. Prior absorption of the specific antibody to TNF-a by nitrocellulose filter-bound recombinant human TNF-a resulted in -50% reduction of gold labeling of the specific granule matrix compartment ( Figure 1D ) compared with the amount of labeling with the sham-absorbed anti-TNF-a control ( Table 1 ).
Discussion
TNFa was localized by a post-embedding immunogold method to the matrix compartment of the bicompartmental major granule population of peripheral blood eosinophils (10-13) obtained from two patients with HES. In contrast, the crystalline core contents of these secondary (specific) granules did not label for TNF-a.
No labeling was detected in other organelles (including small granules, primary granules, tubulovesicular structures, and lipid bodies) or in the plasma membrane, nucleus, or cytoplasm. By assessing many independent stainings of samples obtained from two HES donors, we determined that 64% of the specific granules demonstrated detectable TNF-a in the matrix compartment. Peripheral blood eosinophils from two normal donors did not demonstrate immunogold staining for TNF-a when analyzed with the same postembedding protocol used for the studies of HES eosinophils.
In addition to providing the first ultrastructural localization of any cytokine in eosinophils, this study supports other evidence indicating that expression of TNF-a by eosinophils in HES patients may be greater than that in eosinophils of normal individuals. We recently used LM in situ hybridization (ISH) and immunohistochemistry, as well as Northern blots, to identify TNF-a mRNA and protein in human eosinophils (9). As in the work reported here, the LM studies analyzed eosinophils derived from the peripheral blood of normal donors or of patients with HES. We found that mRNA for TNF-a was detectable in 44-100% of HES eosinophils after only 1 day of exposure of the 35S-labeled ISH preparations (9). In contrast, one of four normal donors exhibited some labeling of 77% of the eosinophils after 1 day of exposure, whereas much lower levels of labeling were detected in the eosinophils of the three other subjects. Moreover, we detected TNF-a protein by immunohistochemistry in 7040% of HES peripheral blood eosinophils but not in eosinophils of normal donors (9). Several lines of evidence indicate that the peripheral blood eosinophils of HES patients are activated cells (10, 16) . Our LM (9) and ultrastructural studies both suggest that augmented expression of TNF-a represents another feature of eosinophil activation in HES.
Ultrastructural immunocytochemical techniques with goldconjugated secondary antibodies have facilitated identification of subcellular sites for a variety of eosinophil constituents (reviewed in 10, 17) . Several proteins with cytotoxic properties (18) are localized to the matrix and the crystalline core compartments of eosinophil-specific granules. These indude major basic protein (crystalline core compartment) and eosinophil-derived neurotoxin, eosinophil cationic protein, and eosinophil peroxidase (matrix compartment). Although the substructural location of these eosinophil granule proteins has been known for some time, the substructural location of a cytokine, such as TNFa, in eosinophils has not previously been determined. Eosinophils have recently been identified as a potential source of several cytokines in addition to TNF-a, including ILla (19) , TGFa (20, 21) , TGFP (22, 23) , GM-CSF (24, 2 5 ) , I L 3 (25), IL5 (26), IL-6 (27), and MIP-la (9) . However, the extent to which the substructural localization of these cytokines resembles that of TNF-a remains to be determined.
